Cassady JM et al. |
Recent developments in the maytansinoid antitumor agents. |
2004 |
Chem. Pharm. Bull. |
pmid:14709862
|
Henry MD et al. |
A prostate-specific membrane antigen-targeted monoclonal antibody-chemotherapeutic conjugate designed for the treatment of prostate cancer. |
2004 |
Cancer Res. |
pmid:15520207
|
Smith SV |
Technology evaluation: cantuzumab mertansine, ImmunoGen. |
2004 |
Curr. Opin. Mol. Ther. |
pmid:15663331
|
Fleming MS et al. |
A reversed-phase high-performance liquid chromatography method for analysis of monoclonal antibody-maytansinoid immunoconjugates. |
2005 |
Anal. Biochem. |
pmid:15840500
|
Wang L et al. |
Structural characterization of the maytansinoid-monoclonal antibody immunoconjugate, huN901-DM1, by mass spectrometry. |
2005 |
Protein Sci. |
pmid:16081651
|
Smith SV |
Technology evaluation: huN901-DM1, ImmunoGen. |
2005 |
Curr. Opin. Mol. Ther. |
pmid:16121706
|
Liu Z et al. |
Metabolism studies of the anti-tumor agent maytansine and its analog ansamitocin P-3 using liquid chromatography/tandem mass spectrometry. |
2005 |
J Mass Spectrom |
pmid:15674857
|
Lu SX et al. |
Mass spectral analyses of labile DOTA-NHS and heterogeneity determination of DOTA or DM1 conjugated anti-PSMA antibody for prostate cancer therapy. |
2005 |
J Pharm Sci |
pmid:15729708
|
Lazar AC et al. |
Analysis of the composition of immunoconjugates using size-exclusion chromatography coupled to mass spectrometry. |
2005 |
Rapid Commun. Mass Spectrom. |
pmid:15945030
|
Frenzel T et al. |
Synthesis of the N-acetylcysteamine thioester of seco-proansamitocin. |
2006 |
Org. Lett. |
pmid:16381586
|
Kubota T et al. |
Determination of the cryptic stereochemistry of the first PKS chain-extension step in ansamitocin biosynthesis by Actinosynnema pretiosum. |
2006 |
Chembiochem |
pmid:16927319
|
Tijink BM et al. |
A phase I dose escalation study with anti-CD44v6 bivatuzumab mertansine in patients with incurable squamous cell carcinoma of the head and neck or esophagus. |
2006 |
Clin. Cancer Res. |
pmid:17062682
|
Kovtun YV et al. |
Antibody-drug conjugates designed to eradicate tumors with homogeneous and heterogeneous expression of the target antigen. |
2006 |
Cancer Res. |
pmid:16540673
|
Floss HG |
Combinatorial biosynthesis--potential and problems. |
2006 |
J. Biotechnol. |
pmid:16414140
|
Erickson HK et al. |
Antibody-maytansinoid conjugates are activated in targeted cancer cells by lysosomal degradation and linker-dependent intracellular processing. |
2006 |
Cancer Res. |
pmid:16618769
|
Widdison WC et al. |
Semisynthetic maytansine analogues for the targeted treatment of cancer. |
2006 |
J. Med. Chem. |
pmid:16821799
|
Wenzel SC et al. |
On the biosynthetic origin of methoxymalonyl-acyl carrier protein, the substrate for incorporation of "glycolate" units into ansamitocin and soraphen A. |
2006 |
J. Am. Chem. Soc. |
pmid:17076505
|
Snipes CE et al. |
The ansacarbamitocins: polar ansamitocin derivatives. |
2007 |
J. Nat. Prod. |
pmid:17892263
|
Goh S et al. |
An integrative expression vector for Actinosynnema pretiosum. |
2007 |
BMC Biotechnol. |
pmid:17956638
|
Sauter A et al. |
Pharmacokinetics, immunogenicity and safety of bivatuzumab mertansine, a novel CD44v6-targeting immunoconjugate, in patients with squamous cell carcinoma of the head and neck. |
2007 |
Int. J. Oncol. |
pmid:17332932
|
Meyer A et al. |
Chemoenzymatic approaches toward dechloroansamitocin P-3. |
2007 |
Org. Lett. |
pmid:17378571
|
Ma J et al. |
New amide N-glycosides of ansamitocins identified from Actinosynnema pretiosum. |
2007 |
Arch. Pharm. Res. |
pmid:17679541
|
Reddy JA et al. |
Folate receptor-specific antitumor activity of EC131, a folate-maytansinoid conjugate. |
2007 |
Cancer Res. |
pmid:17616697
|
Galsky MD et al. |
Phase I trial of the prostate-specific membrane antigen-directed immunoconjugate MLN2704 in patients with progressive metastatic castration-resistant prostate cancer. |
2008 |
J. Clin. Oncol. |
pmid:18362364
|
Arai MA et al. |
Hedgehog/GLI-mediated transcriptional inhibitors from Zizyphus cambodiana. |
2008 |
Bioorg. Med. Chem. |
pmid:18842418
|
Lewis Phillips GD et al. |
Targeting HER2-positive breast cancer with trastuzumab-DM1, an antibody-cytotoxic drug conjugate. |
2008 |
Cancer Res. |
pmid:19010901
|
Riechelmann H et al. |
Phase I trial with the CD44v6-targeting immunoconjugate bivatuzumab mertansine in head and neck squamous cell carcinoma. |
2008 |
Oral Oncol. |
pmid:18203652
|
Chari RV |
Targeted cancer therapy: conferring specificity to cytotoxic drugs. |
2008 |
Acc. Chem. Res. |
pmid:17705444
|
Rodon J et al. |
Cantuzumab mertansine in a three-times a week schedule: a phase I and pharmacokinetic study. |
2008 |
Cancer Chemother. Pharmacol. |
pmid:18301896
|
Ishitsuka K et al. |
Targeting CD56 by the maytansinoid immunoconjugate IMGN901 (huN901-DM1): a potential therapeutic modality implication against natural killer/T cell malignancy. |
2008 |
Br. J. Haematol. |
pmid:18279455
|
Taft F et al. |
Highly active ansamitocin derivatives: mutasynthesis using an AHBA-blocked mutant. |
2008 |
Chembiochem |
pmid:18381586
|
Ostermann E et al. |
Effective immunoconjugate therapy in cancer models targeting a serine protease of tumor fibroblasts. |
2008 |
Clin. Cancer Res. |
pmid:18628473
|
Stephan JP et al. |
Anti-CD22-MCC-DM1 and MC-MMAF conjugates: impact of assay format on pharmacokinetic parameters determination. |
2008 |
Bioconjug. Chem. |
pmid:18637680
|
Zhao P et al. |
Amide N-glycosylation by Asm25, an N-glycosyltransferase of ansamitocins. |
2008 |
Chem. Biol. |
pmid:18721757
|
Polson AG et al. |
Antibody-drug conjugates for the treatment of non-Hodgkin's lymphoma: target and linker-drug selection. |
2009 |
Cancer Res. |
pmid:19258515
|
Taft F et al. |
Timing of the Delta(10,12)-Delta(11,13) double bond migration during ansamitocin biosynthesis in Actinosynnema pretiosum. |
2009 |
J. Am. Chem. Soc. |
pmid:19292483
|
Wang L et al. |
Formal total synthesis of N-methylmaysenine. |
2009 |
Org. Lett. |
pmid:19296671
|
Ikeda H et al. |
The monoclonal antibody nBT062 conjugated to cytotoxic Maytansinoids has selective cytotoxicity against CD138-positive multiple myeloma cells in vitro and in vivo. |
2009 |
Clin. Cancer Res. |
pmid:19509164
|
Al-Katib AM et al. |
Superior antitumor activity of SAR3419 to rituximab in xenograft models for non-Hodgkin's lymphoma. |
2009 |
Clin. Cancer Res. |
pmid:19509168
|
Tang R et al. |
P-gp activity is a critical resistance factor against AVE9633 and DM4 cytotoxicity in leukaemia cell lines, but not a major mechanism of chemoresistance in cells from acute myeloid leukaemia patients. |
2009 |
BMC Cancer |
pmid:19549303
|
Ng D et al. |
Constitutive overexpression of asm2 and asm39 increases AP-3 production in the actinomycete Actinosynnema pretiosum. |
2009 |
J. Ind. Microbiol. Biotechnol. |
pmid:19609582
|
Zheng B et al. |
In vivo effects of targeting CD79b with antibodies and antibody-drug conjugates. |
2009 |
Mol. Cancer Ther. |
pmid:19808977
|
Haeuw JF et al. |
[Immunoconjugates, drug-armed antibodies to fight against cancer]. |
2009 |
Med Sci (Paris) |
pmid:20035677
|
Lutz RJ and Whiteman KR |
Antibody-maytansinoid conjugates for the treatment of myeloma. |
2009 Nov-Dec |
MAbs |
pmid:20068397
|
Monneret C |
[Current impact of natural products in the discovery of anticancer drugs]. |
2010 |
Ann Pharm Fr |
pmid:20637355
|
Higa GM et al. |
Biological considerations and clinical applications of new HER2-targeted agents. |
2010 |
Expert Rev Anticancer Ther |
pmid:20836684
|
Lopus M et al. |
Maytansine and cellular metabolites of antibody-maytansinoid conjugates strongly suppress microtubule dynamics by binding to microtubules. |
2010 |
Mol. Cancer Ther. |
pmid:20937594
|
Oroudjev E et al. |
Maytansinoid-antibody conjugates induce mitotic arrest by suppressing microtubule dynamic instability. |
2010 |
Mol. Cancer Ther. |
pmid:20937595
|
Krop IE et al. |
Phase I study of trastuzumab-DM1, an HER2 antibody-drug conjugate, given every 3 weeks to patients with HER2-positive metastatic breast cancer. |
2010 |
J. Clin. Oncol. |
pmid:20421541
|
Jumbe NL et al. |
Modeling the efficacy of trastuzumab-DM1, an antibody drug conjugate, in mice. |
2010 |
J Pharmacokinet Pharmacodyn |
pmid:20424896
|